Artificial Intelligence Drug Discovery and Development
DOI:
https://doi.org/10.22270/ajprd.v13i6.1657Abstract
The integration of Artificial Intelligence (AI) into drug discovery and development has revolutionized the pharmaceutical landscape by enabling faster, cost-effective, and data-driven innovations. Traditional drug discovery methods are time-consuming and expensive, often requiring over a decade and billions of dollars to bring a new drug to market. AI technologies such as Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP) significantly enhance each stage of the drug discovery pipeline—from target identification and virtual screening to lead optimization, toxicity prediction, and clinical trial design. By analyzing complex biological, chemical, and clinical datasets, AI facilitates the discovery of novel therapeutic targets, predicts molecular interactions, and improves drug safety and efficacy. Moreover, generative AI models accelerate de novo drug design, while AI-driven analytics enable personalized medicine and drug repurposing. Despite challenges such as data bias, interpretability, and regulatory constraints, AI’s transformative potential continues to reshape pharmaceutical research, offering a faster, more efficient, and precise approach to developing next-generation therapeutics.
Downloads
References
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26(1):80–93.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.
Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773–80.
Lo YC, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. Drug Discov Today. 2018;23(8):1538–46.
Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2021;3(10):957–68.
Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435–41.
Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharm. 2020;17(12):4313–30.
Walters WP, Murcko MA, Muratov EN. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol. 2021;39(11):1299–302.
Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M. Advances in artificial intelligence for drug delivery and development: A comprehensive review. Comput Biol Med. 2024;178:108702.
Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz AM, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.
Schneider G, Clark DE, Hunt P. Artificial intelligence in medicinal chemistry: Hype or hope? J Med Chem. 2020; 63(16):8659–63.
Singh N, Vayer P, Tanwar S, Poyet JL, Tsaioun K, Villoutreix BO. Drug discovery and development: Introduction to the general public and patient groups. Front Drug Discov. 2023; 3:1201419.
Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals. 2023; 16(6):891.
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011; 162(6):1239–49.
ZeClinics. Drug discovery and development: A step-by-step process. Ze Clinics [Internet]. 2025 [cited 2025 Oct 26].
U.S. Food and Drug Administration. The drug development process. FDA [Internet]. 2018 [cited 2025 Oct 26].
Sun J, Zhu K, Zheng W, Chen J. Artificial intelligence in clinical trial design and drug development: Current applications and future perspectives. Drug Discovery Today. 2022; 27(11):103341.
Ferreira FJN, Carneiro AS. AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega. 2025; 10(23):23889-23903.
Serrano DR, et al. Artificial intelligence (AI) applications in drug discovery and development: An overview. Front Pharmacol. 2024.
Kim H, et al. Artificial intelligence in drug discovery: A comprehensive review. Biomolecules. 2021; 11(9):1245.
Askr H, et al. Deep learning in drug discovery: An integrative review and perspective. Comput Struct Biotechnology J. 2022.
Hasselgren C. Artificial intelligence for drug discovery: Are we there yet? Annu Rev Pharmacol Toxicol. 2024.
Dhudum R. Revolutionizing drug discovery: A comprehensive review. AI. 2024;3(1):9
Koutroumpa NM, et al. A systematic review of deep learning methodologies in drug discovery. Int J Mol Sci. 2023;24(7):6573.
Singh S. Application of artificial intelligence in drug design: A review. J Pharm Innov. 2024.
Zhou Y, Wang F, Tang J, Niu X. Semi-supervised learning in drug discovery: Current progress and future opportunities. Front Pharmacol. 2021;12:667714.
Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2021;26(2):511–24
Honda S, Inoue M, Ishikawa T. Transformer-based models for molecular generation and property prediction. Brief Bioinform. 2023;24(2):bbac629.
Zhou J, Cui G, Hu S, Zhang Z, Yang C, Liu Z, Sun M. Graph neural networks: A review of methods and applications in chemistry. Chem Rev. 2023;123(7):4536–87.
Blaschke T, Olivecrona M, Engkvist O, Bajorath J, Chen H. Application of generative autoencoder in de novo molecular design. Mol Inform. 2020;39(1–2):1900123.
Sanchez-Lengeling B, Aspuru-Guzik A. Inverse molecular design using machine learning: Generative models for matter engineering. Science. 2018;361(6400):360–5.
Walters WP, Murcko MA. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol. 2020;38(2):143–5.
Xiong Z, Wang D, Liu X, Zhong F, Wan D, Zeng J. Evaluating explainable artificial intelligence approaches for molecular property prediction. Chem Sci. 2022;13(4):1203–14.
Zhou Y, Wang F, Tang J, Niu J, Li Y. Artificial intelligence in drug discovery: Applications and techniques. Brief Bioinform. 2020;21(5):1760–76.
Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnology. 2019;37(9):1038–40. https://doi.org/10.1038/s41587-019-0224-x 36.
Wallach I, Dzamba M, Heifets A. AtomNet: A deep convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv preprint. 2015: arXiv:1510.02855.
Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, et al. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent Sci. 2018;4(2):268–76.
Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604–10.
Yang Y, Li J, Wang X. Machine learning in ADMET prediction: Recent applications and challenges. Front Pharmacology. 2022;13:812693. https://doi.org/10.3389/fphar.2022.812693
Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317–8.
Amazon Web Services. Driving innovation in drug discovery using generative AI with Bayer. AWS Blog [Internet]. 2024 [cited 2025 Oct 26].
Labiotech.eu. Best AI drug discovery companies in 2024. Labiotech.eu [Internet]. 2024 [cited 2025 Oct 26].
The Times. Exscientia bought for $688m by American pharma business Recursion. The Times [Internet]. 2024 Oct 12 [cited 2025 Oct 26].
Reuters. NVIDIA-backed AI firm Iambic unveils drug discovery breakthrough. Reuters [Internet]. 2024 Oct 29 [cited 2025 Oct 26].
The Guardian. AI used to predict potential new antibiotics in groundbreaking study. The Guardian [Internet]. 2024 Jun 5 [cited 2025 Oct 26].
Jumper J, Evans R, Pritzel A, Green T, Hassabis D, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9. doi:10.1038/s41586-021-03819-2
Reuters. US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership. Reuters [Internet]. 2025 Oct 14 [cited 2025 Oct 26].
Times of India. Google DeepMind ready to start human trials of AI-designed drugs; company exec says, “We’re getting very close.” 2025 Jul 3.
Evaxion Biotech. AI-driven immunotherapy and vaccine design. 2024.
BenevolentAI. Accelerating drug discovery with AI. 2024.
Healx. AI-powered drug repurposing for rare diseases. 2025.
Haghighi M, et al. Multi-omics phenomics and AI in drug discovery. Cell Syst. 2025;16(1):12–28.
Huang K, Fu T, Glass LM, et al. Artificial intelligence in drug discovery: Recent advances and future perspectives. Drug Discovery Today. 2021;26(9):2233–47.
Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2020;25(2):293–9.
Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.
Zhang Q, Li Y, Wang J. Bridging AI and life sciences: Interdisciplinary approaches in drug discovery. Brief Bioinformation. 2024;25(3):bbad123.
Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
Li L, Zeng L, Gao Z, et al. In Drug: A benchmark for deep imbalanced learning in AI-aided drug discovery. arXiv [Preprint]. 2022.
Ghislat G, Hernandez-Hernandez S, Piyawajanusorn C, Ballester PJ. Data-centric challenges with the application and adoption of artificial intelligence for drug discovery. ArXiv [Preprint]. 2024.
Bhushan A, et al. Unlocking the potential: Multimodal AI in biotechnology. Nat Biotechnology. 2025.
Hassabis D. AI could cut drug discovery from years to months. Times of India. 2025 Oct 14.
Foppen RJG, Gioia V, Zoccoli A. Early evidence and emerging trends: How AI is shaping drug discovery and clinical development. Drug Target Rev. 2025.
Jarallah SJ. Artificial intelligence revolution in drug discovery. SciDirect. 2025.
Yadav S. Revolutionizing drug discovery: The impact of artificial intelligence [Internet]. ScienceDirect; 2024 [cited 2025 Oct 26].
Pharma Advancement. AI revolutionizing drug discovery and clinical development [Internet]. Pharma Advancement; 2025 [cited 2025 Oct 26].
Das U. Generative AI for drug discovery and protein design. Med Drug Discov. 2025; 27:100213.
European Medicines Agency. Review of artificial intelligence and machine learning applications in the medicine lifecycle [Internet]. EMA; 2024 [cited 2025 Oct 26].
Reuters. US FDA to phase out animal testing in drug development [Internet]. Reuters; 2025 Apr 10 [cited 2025 Oct 26]. Available from: https://www.reuters.com/world/us/us-fda-phase-out-animal-testing-drug-development-2025-04-10/
arXiv. Self-driving labs and AI integration in drug discovery [Internet]. arXiv; 2025 [cited 2025 Oct 26].
Genetic Engineering & Biotechnology News. The state of AI in drug discovery 2025 [Internet]. Genetic Engineering & Biotechnology News; 2025 [cited 2025 Oct 26].
Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–50.
Li X, Zhang Z. Artificial intelligence in drug repurposing. Curr Opin Pharmacol. 2020;54:43–50.
Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
Shang L, Liu Y. Artificial intelligence in clinical trials: Applications and perspectives. Front Pharmacol. 2021;12:629707.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Subedar Ikra A, Bhandare Sangita N.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 